Eli Lilly (LLY) Assets Average (2009 - 2026)

Eli Lilly has reported Assets Average for 18 years, with the latest figure at $114.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 36.26% year-over-year to $114.5 billion; the trailing twelve-month figure through Mar 2026 stood at $114.5 billion (up 36.26% YoY), and the FY2025 full-year result was $95.6 billion, up 33.96% from the prior year.
• Assets Average for Q1 2026 stood at $114.5 billion, up from $113.7 billion in the prior quarter.
• The five-year high for Assets Average was $114.5 billion in Q1 2026, with the low at $47.0 billion in Q2 2022.
• Historically, Assets Average has averaged $71.3 billion across 5 years, with a median of $64.0 billion in 2024.
• Annual changes were most pronounced in 2022 — Assets Average decreased 1.53% — and 2025, when it surged 47.36%.
• Eli Lilly's Assets Average stood at $48.5 billion in 2022, then advanced by 25.76% to $61.0 billion in 2023, then gained by 26.57% to $77.2 billion in 2024, then soared by 47.36% to $113.7 billion in 2025, then climbed by 0.72% to $114.5 billion in 2026.
• The last three Assets Average figures came in at $114.5 billion (Q1 2026), $113.7 billion (Q4 2025), and $107.9 billion (Q3 2025), per Business Quant data.